Results 51 to 60 of about 6,272,911 (310)
ABSTRACT Background Survivors of pediatric brain tumors (PBTs) can experience long‐term social difficulties, impacting quality of life. Beyond medical and environmental factors, family psychosocial risk may play a role in social outcomes by shaping the caregiving environment and may provide intervention options.
Renske H. Houben +4 more
wiley +1 more source
Posaconazole Therapeutic Drug Monitoring in a Regional Hospital Setting
Background: Posaconazole therapeutic drug monitoring (TDM) is recommended to promote effective antifungal prophylaxis, but its utility has yet to be optimized. Breakthrough invasive fungal infections have been reported with serum concentrations
Patrick J. Lindsay +9 more
core +1 more source
ABSTRACT Background Allogeneic hematopoietic stem cell transplantation (alloHSCT) is an essential therapy for several malignant and nonmalignant diseases, but relapse and graft loss remain the principal threats to its success. Routine monitoring of chimerism and minimal residual disease (MRD) enables early detection of imminent recurrence and guides ...
Carmen Junk +10 more
wiley +1 more source
Cytokines are small, membrane-bound, protein-based cell signaling molecules that aid cell-to-cell communication in physiological and pathological processes. TNF-α is a pleiotropic cytokine that is regarded as a principal cytokine in the acute and chronic
Marta Białecka +4 more
doaj +1 more source
Therapeutic Drug Monitoring in Inflammatory Bowel Disease
Inflammatory bowel disease (IBD) is a problem that directly affects the quality of life of patients suffering from this condition. Monitoring the serum level of infliximab (IFX) (TDM) is an important tool for guiding therapeutic decisions in IBD patients.
Manoel Alvaro de Freitas Lins Neto +6 more
doaj +1 more source
ABSTRACT Background Reduced bone mineral density (BMD) has been reported in survivors of childhood and young adult acute lymphoblastic leukaemia (ALL); however, data from cohorts treated with contemporary protocols and including matched controls remain limited.
Karen Schow Jensen +10 more
wiley +1 more source
Therapeutic Drug Monitoring of Ziprasidone in a Clinical Treatment Setting
There is limited information on the pharmacokinetics of ziprasidone (ZIP) in naturalistic clinical settings. The objective of this study was to investigate the concentrations of ZIP and its active metabolite S-methyl-dihydroziprasidone (SMDZ), and the ...
Reis, Margareta, +4 more
core +1 more source
Monographs on drugs which are frequently analyzed in therapeutic drug monitoring [PDF]
In addition to the monographs which have been published recently by the working group "Drug Monitoring” of the Swiss Society of Clinical Chemistry (SSCC) [1-3], new monographs have been written.
Grignaschi, M +24 more
core +2 more sources
ABSTRACT Pediatric intramedullary low‐grade gliomas (PIMLGGs) are rare neoplasms that present unique clinical and management challenges. Although surgery remains the primary tool for tissue diagnosis and decompression, complete gross‐total resection is frequently unfeasible due to the infiltrative nature of these lesions.
Olga M. Sergeenko +5 more
wiley +1 more source
Olanzapine (Zyprexa«) was approved for general prescription in Sweden in November 1996, and an HPLC-based therapeutic drug monitoring (TDM) routine for serum olanzapine (OLA) and its major metabolite, N-demethylolanzapine (DMO) was established in ...
Reis, Margareta, +9 more
core +1 more source

